ConductScience.org, home

Paper33764385

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.

Del Paggio JC and 6 others. JAMA Oncol, 2021. Cited by 185 papers, by iCite.

Cite this record

ConductScience Library. Evolution of the Randomized Clinical Trial in the Era of Precision Oncology. Papers, record 33764385. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/33764385

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Evolution of the Randomized Clinical Trial in the Era of Precision Oncology.
PubMed
Journal
JAMA Oncol
PubMed
Year
2021
PubMed
Publication types
Journal Article, Randomized Controlled Trial
PubMed
Citations, by iCite
185
iCite
Relative citation ratio, by iCite
8.56
iCite
Revised in PubMed
2024-04-07
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Del Paggio JCJoseph C
2Berry JSJohn S
3Hopman WMWilma M
4Eisenhauer EAElizabeth A
5Prasad VVinay
6Gyawali BBishal
7Booth CMChristopher M

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, Non-Small-Cell LungMajor topic
Lung NeoplasmsMajor topic
Drug Industry
Humans
Medical Oncology
Progression-Free Survival

Comments and corrections4

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in34436516Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity-Reply.https://conductscience.org/library/papers/34436516PubMed
Comment in34436547Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.https://conductscience.org/library/papers/34436547PubMed
Comment in34436567Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.https://conductscience.org/library/papers/34436567PubMed
Comment in34436578Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity.https://conductscience.org/library/papers/34436578PubMed

Download CSV of comments and corrections

References30

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126101248American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options.J Clin Oncol2015https://conductscience.org/library/papers/26101248PubMed
224803662High cancer drug prices in the United States: reasons and proposed solutions.J Oncol Pract2014https://conductscience.org/library/papers/24803662PubMed
332885898Professional Medical Writer Assistance in Oncology Clinical Trials.Oncologist2020https://conductscience.org/library/papers/32885898PubMed
422048151Randomized controlled trials in the era of molecular oncology: methodology, biomarkers, and end points.Ann Oncol2012https://conductscience.org/library/papers/22048151PubMed
522370321Progression-free survival: meaningful or simply measurable?J Clin Oncol2012https://conductscience.org/library/papers/22370321PubMed
628453694Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000-2015.Ann Oncol2017https://conductscience.org/library/papers/28453694PubMed
728978555Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13.BMJ2017https://conductscience.org/library/papers/28978555PubMed
827281466An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials.JAMA Oncol2016https://conductscience.org/library/papers/27281466PubMed
928027518Impact of industry collaboration on randomised controlled trials in oncology.Eur J Cancer2017https://conductscience.org/library/papers/28027518PubMed
1030374970Association between progression-free survival and patients' quality of life in cancer clinical trials.Int J Cancer2019https://conductscience.org/library/papers/30374970PubMed
1133507236An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries.JAMA Oncol2021https://conductscience.org/library/papers/33507236PubMed
1230285081Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology: A Systematic Review and Quantitative Analysis.JAMA Intern Med2018https://conductscience.org/library/papers/30285081PubMed
1320525992Improved survival with ipilimumab in patients with metastatic melanoma.N Engl J Med2010https://conductscience.org/library/papers/20525992PubMed
1419951955Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer.Ann Oncol2010https://conductscience.org/library/papers/19951955PubMed
1510968436The uncertainty principle and industry-sponsored research.Lancet2000https://conductscience.org/library/papers/10968436PubMed
1632815984Association of Industry Sponsorship With Cancer Clinical Trial Accrual.JAMA Oncol2020https://conductscience.org/library/papers/32815984PubMed
1733412270Have investigators forgotten how to write?Ann Oncol2021https://conductscience.org/library/papers/33412270PubMed
1830572165New clinical trial designs in the era of precision medicine: An overview of definitions, strengths, weaknesses, and current use in oncology.Cancer Treat Rev2019https://conductscience.org/library/papers/30572165PubMed
1928583794Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.Lancet Oncol2017https://conductscience.org/library/papers/28583794PubMed
2026098871The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.JAMA Intern Med2015https://conductscience.org/library/papers/26098871PubMed

See all 30 referencesDownload CSV of references

Cited by103

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 185 citations.

PMIDTitleJournalYearIn PapersSource
42985096Optimizing first-line therapy for advanced EGFR-mutated NSCLC: a patient-centered approach for low- and middle- income countries.Front Oncol2026https://conductscience.org/library/papers/42985096PubMed
42789933Overall survival in oncology phase III trials: an individual patient level meta-analysis (OPTIMA).Oncologist2026https://conductscience.org/library/papers/42789933PubMed
42740735Clinical practice guideline recommendations can promote or undermine health equity.Clin Public Health Guidel2025https://conductscience.org/library/papers/42740735PubMed
42583054An overview of clinical trials in anal cancer 1999-2024.ESMO Gastrointest Oncol2026https://conductscience.org/library/papers/42583054PubMed
42518588Longitudinal changes in the relative toxicity of FDA-approved oncology therapeutics: evidence from paired initial and updated RCT reports.Front Public Health2026https://conductscience.org/library/papers/42518588PubMed
42518232Drug Costs in Federally Sponsored Cancer Clinical Trials: A Systematic Review.JAMA Netw Open2026https://conductscience.org/library/papers/42518232PubMed
42465577Comparative study of three treatment approaches on overall survival and treatment response in nasopharyngeal carcinoma patients: network meta-analysis of RCTs (4221 patients).Front Oncol2026https://conductscience.org/library/papers/42465577PubMed
42448890Using CA1 rather than the whole hippocampus to capture tau-PET Braak stage II.Eur J Nucl Med Mol Imaging2026https://conductscience.org/library/papers/42448890PubMed
42443603Evolution of randomized controlled trials in adult neurosurgical critical care from 1990 to 2024 in the United States.Neurosurg Rev2026https://conductscience.org/library/papers/42443603PubMed
42406651Progression-Free Survival Effect Sizes in Randomized Controlled Trials of Targeted Cancer Therapies with Positive Outcomes.Acta Haematol2026https://conductscience.org/library/papers/42406651PubMed
42270817Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement.Nat Rev Clin Oncol2026https://conductscience.org/library/papers/42270817PubMed
41915264The use of endpoints in phase 3 randomized controlled trials in metastatic breast cancer.Breast Cancer Res Treat2026https://conductscience.org/library/papers/41915264PubMed
41889619From methods to policy: a critical appraisal of the 2024 ECDC guidance on enhanced influenza vaccines.Front Public Health2026https://conductscience.org/library/papers/41889619PubMed
41777410Oncology with common sense: beyond biologistic and pharmacological models.Ecancermedicalscience2026https://conductscience.org/library/papers/41777410PubMed
41699553Accelerating cancer therapy review: a cross-sectional analysis of expedited approval in China, 2005-2021.BMC Cancer2026https://conductscience.org/library/papers/41699553PubMed
41694651Surrogate Endpoints for Overall Survival in Advanced Hepatocelluar Carcinoma in the Era of Immunotherapy: A Trial Level Meta-Analysis.Liver Cancer2026https://conductscience.org/library/papers/41694651PubMed
41688575Comparison of primary analysis strategies of randomized controlled trials with multiple endpoints with application to kidney transplantation.Sci Rep2026https://conductscience.org/library/papers/41688575PubMed
41647347
Definitions, measurement, and reporting of progression-free survival in randomized clinical trials and observational studies of patients with advanced non-small-cell lung cancer treated with immunotherapy: a scoping review.
ESMO Real World Data Digit Oncol2025https://conductscience.org/library/papers/41647347PubMed
41512959Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum.J Cancer Policy2026https://conductscience.org/library/papers/41512959PubMed
41491679Patient preference for first-line treatments of ALK-positive metastatic non-small cell lung cancer: a discrete choice experiment.BMC Cancer2026https://conductscience.org/library/papers/41491679PubMed

See all 103 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/33764385

GET https://conductscience.org/api/papers/v1/33764385/references?page=2